Fischer will join Fresenius Medical Care as CFO starting on Oct. 1, the company announced Monday. The Germany-based firm, which makes dialysis products and operates a network of clinics, has shuffled its leadership as parent company Fresenius plans to spin out the unit by the end of the year.
In December, Fresenius Medical Care promoted CFO Helen Giza to CEO. Giza will continue to serve as acting CFO for the company until Fischer starts this fall. When the company becomes a German stock corporation, Fischer will become a member of Fresenius Medical Care’s board.
“Martin Fischer has proven that he can successfully drive fundamental change in organizations. In our organizational transformation and turnaround management, we will benefit from his finance and healthcare expertise,” Giza said in a statement. “Martin will be an important contributor to the execution of our strategy in unlocking value as the leading kidney care company.”
Fischer joins the company after working as head of finance for the Siemens Healthineers Diagnostic Division. Before that, he held other operational and finance positions at Siemens.
He will be based in Bad Homburg, Germany, and will be responsible for Fresenius Medical Care’s global finance.
by Elise Reuter
Source: medtechdive.com
After attending the annual Pulmonary Embolism Symposium last week in Austin, Texas, the analysts predicted clinical guidelines could shift toward catheter-based therapy once data from ongoing randomized trials is available.
SAS – the AI and analytics company – has been selected by AstraZeneca to help boost efficiency and drive automation in the delivery of statistical analyses for clinical and post-approval submissions to regulatory authorities.
After the Centers for Medicare & Medicaid Services (CMS) revealed the list of drugs set to face the first round of price negotiations under the Inflation Reduction Act (IRA), the drugmakers responsible for marketing them are confronting a series of deadlines.
